ClinicalTrials.gg
CompletedNCT07585591Updated May 14, 2026

Safety and Efficacy Evaluation of the Xerf Device for Aesthetic Treatments

An interventional study of Noninvasive dual-frequency monopolar radiofrequency in Facial Aging, Facial Skin Laxity and Submental and Neck Skin Laxity, sponsored by CynosureLutronic. Completed at 4 sites in United States. Open to participants aged 22 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by CynosureLutronic · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 3 months ago, and no results have been posted to the registry.
  • Registered 1 year after the study started (first participant enrolled Jan 2025, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
22 Years to 70 Years
Sex
All
01

Study summary

The goal of this clinical study is to evaluate the safety and clinical effectiveness of the XERF noninvasive dual-frequency monopolar radiofrequency device for aesthetic improvement of facial aging, including fine lines and wrinkles, eyebrow lifting, and tightening of lax tissue in the lower face, submental area, and neck in healthy adults.

Up to 60 participants may be enrolled across up to five clinical sites in the United States. Participants receive XERF treatments using 6.78 MHz and 2.0 MHz energy; most undergo two sessions approximately four weeks apart (the protocol allows up to three). Standardized photographs are taken at baseline and follow-up visits.

Outcomes are assessed approximately 30 and 90 days after the final treatment. Effectiveness is evaluated using investigator-assessed global aesthetic improvement and participant-reported satisfaction, while safety and tolerability are assessed through procedural pain ratings and monitoring of adverse events throughout the study.

02

Conditions studied

  • Facial Aging
  • Facial Skin Laxity
  • Submental and Neck Skin Laxity
03

In context

Lead sponsor

CynosureLutronic is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 22 - 70 years old
  • Is willing to undergo study device use.
  • Has not received any toxin/filler in the treatment area in the past 6 months and agrees to not receive any throughout the study.
  • Willing to maintain current diet and exercise routine throughout study duration.
  • Understands and accepts the study condition to not receive any other procedures to the treatment area or to undergo any procedures, take any medications, supplements, or partake in any treatments indicated for weight loss or body contouring throughout the length of the study.
  • Understands and accepts the study condition of and agrees that he or she is able to be present for all study visits.
  • Willing to comply with all requirements of the study and is able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding, or planning a pregnancy during the study period.
  • Has an implanted pacemaker, internal ventricular fibrillation controller (AICD), or any electrical device.
  • Has a metal implant that interferes with the transmission of energy to the electrical field.
  • Has received permanent fillers or facial implants.
  • Has a detected pathological abnormality.
  • Has a medical condition with potentially decreased function of the peripheral nervous tissue, such as but not limited to diabetes or multiple sclerosis.
  • Has an infection or infected tissue in the treatment area.
  • Unable or not willing to follow instructions for pre- and post-treatment care
  • Recent history of smoking (1 month)
  • Has unrealistic treatment expectations.
  • Has a history of herpes simplex in which the patient is not willing/able to receive preventive antiviral therapy.
  • Has a blood disorder and taking aspirin or blood disorder medications.
  • Has a malignant disease, cancer, or uncontrolled disease.
  • Had previous surgical or cosmetic procedures in the treatment area in the last 3 months that could interfere with the treatment procedure (including but not limited to dermabrasion, chemical peels, laser skin resurfacing, fat augmentations, topical retinoids and radiofrequency treatments)
  • Currently enrolled in an drug or device trial, or has received an investigational drug or been treated with an investigational device within the area to be treated 6 months prior to entering this study
  • Has any condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound study results, or may interfere significantly with the subject's participation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    XERF Treatment

    Device: Noninvasive dual-frequency monopolar radiofrequency

Interventions

  • DeviceNoninvasive dual-frequency monopolar radiofrequency

    Participants received treatment with a noninvasive contact monopolar radiofrequency (RF) device (XERF) operating at 6.78 MHz and 2.0 MHz. The device delivers RF energy using depth-dependent settings (Shallow, Middle, and Deep) selected based on the target condition and facial anatomic zone. Treatments were performed with the EFFECTOR 60 tip using sliding mode, stamping mode, or a combination, after facial cleansing and application of a thin film of ultrasound gel. Adjustable cryogen gas cooling (ICD Levels 1-3) was used for epidermal protection and comfort; no topical anesthesia was used. Participants underwent two treatment sessions approximately 4 weeks apart (the protocol allowed up to three sessions). The number of shots and total energy delivered (joules) were recorded for each treatment area.

06

What researchers measure

Primary outcomes

  1. Clinician-Scored Global Aesthetic Improvement Scale (GAIS) Responder Rate

    Proportion of participants with a GAIS score ≥3 (on a 5-point scale, 1-5), assessed by site principal investigators using standardized clinical photographs. A GAIS score ≥3 was considered an effective clinical improvement.

    Time frame: 90 days after the final treatment

Secondary outcomes

  1. Patient Satisfaction Score (PSS) Responder Rate

    Proportion of participants with a Patient Satisfaction Score (PSS) ≥4 on a 6-point scale (1 = extreme dissatisfaction; 6 = significant satisfaction), assessed at follow-up visits.

    Time frame: 30 and 90 days after the final treatment

  2. Clinician-Scored Global Aesthetic Improvement Scale (GAIS) Responder Rate at 30 Days

    Proportion of participants with a GAIS score ≥3 on a 5-point scale (1-5), assessed by site principal investigators using standardized clinical photographs. GAIS ≥3 was considered effective improvement.

    Time frame: 30 days after the final treatment

  3. Incidence of Adverse Events

    Number and proportion of participants experiencing treatment-emergent adverse events, documented throughout the study and follow-up.

    Time frame: From first treatment through 90 days after the final treatment

07

Study locations

4 sites
  • Oak Dermatology
    Naperville, Illinois 60563, United States
  • Maryland Dermatology Laser, Skin, & Vein Institute, LLC
    Hunt Valley, Maryland 21030, United States
  • New Jersey Plastic Surgery
    Montclair, New Jersey 07042, United States
  • Laser & Skin Surgery Center of Pennsylvania
    Devon, Pennsylvania 19333, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Aug 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
May 14, 2026
StartActual
Jan 20, 2025
Primary completionActual
Aug 12, 2025
CompletionActual
Aug 12, 2025
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07585591
Lead sponsor
CynosureLutronic
Responsible party
Sponsor
First posted
May 14, 2026
Start date
Jan 20, 2025
Primary completion
Aug 12, 2025
Completion
Aug 12, 2025
Last update
May 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion